These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23889894)
1. Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report. Iannetti L; Abbouda A; Fabiani C; Zito R; Campanella M J Med Case Rep; 2013 Jul; 7():199. PubMed ID: 23889894 [TBL] [Abstract][Full Text] [Related]
3. Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab. Cavallini GM; Pellegrini G; Volante V; Ducange P; De Maria M; Torlai G; Benatti C; Forlini M Clin Ophthalmol; 2014; 8():1671-3. PubMed ID: 25210437 [TBL] [Abstract][Full Text] [Related]
4. Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab. Britton AK; Crayford BB Case Rep Ophthalmol; 2020; 11(3):652-657. PubMed ID: 33442379 [TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. You IC; Im SK; Lee SH; Yoon KC Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729 [TBL] [Abstract][Full Text] [Related]
6. Avastin use in high risk corneal transplantation. Vassileva PI; Hergeldzhieva TG Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1701-6. PubMed ID: 19680676 [TBL] [Abstract][Full Text] [Related]
9. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Acar BT; Halili E; Acar S Int Ophthalmol; 2013 Oct; 33(5):507-13. PubMed ID: 23404727 [TBL] [Abstract][Full Text] [Related]
10. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Dastjerdi MH; Saban DR; Okanobo A; Nallasamy N; Sadrai Z; Chauhan SK; Hajrasouliha AR; Dana R Invest Ophthalmol Vis Sci; 2010 May; 51(5):2411-7. PubMed ID: 19892863 [TBL] [Abstract][Full Text] [Related]
11. Subconjunctival bevacizumab for corneal neovascularization. Erdurmus M; Totan Y Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556 [TBL] [Abstract][Full Text] [Related]
12. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. Jeong S; Sagong M; Chang W BMC Ophthalmol; 2017 Mar; 17(1):25. PubMed ID: 28288603 [TBL] [Abstract][Full Text] [Related]
18. Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty. Lakshmipathy M; Susvar P; Popet K; Rajagopal R Indian J Ophthalmol; 2019 Jul; 67(7):1193-1194. PubMed ID: 31238461 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. You IC; Kang IS; Lee SH; Yoon KC Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596 [TBL] [Abstract][Full Text] [Related]
20. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model. Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]